Research on psilocybin alcohol use disorder treatment, including a landmark 2022 randomized controlled trial published in JAMA Psychiatry, has shown meaningful reductions in heavy drinking days compared to placebo. The findings are significant, but the research is...
Interest in psychedelics and creativity among executives has moved well beyond Silicon Valley. Neuroscientific research points to measurable changes in divergent thinking, cognitive flexibility, and problem-solving in the days and weeks following a supported...
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single guided dose can produce meaningful, lasting reductions in PTSD symptoms. The evidence is promising, but also...
The default mode network is a cluster of brain regions responsible for self-referential thinking, rumination, and your ongoing sense of “I.” Research on default mode network psychedelics shows that psilocybin temporarily disrupts this network’s rigid...
Psychedelic therapy for executives is moving beyond reputation and into clinical evidence. A growing number of C-suite leaders are using professionally supported psilocybin and ketamine experiences to address burnout, decision fatigue, and stalled thinking. Here is...
Quick Answer Psilocybin and other psychedelics show real, measurable promise for depression, particularly treatment-resistant cases. But the evidence in 2026 is more complicated, more honest, and more nuanced than headlines suggest. Whether this path is right for you...
